(Q35232016)

7 August 2017

1 reference

title

Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: combination therapy (English)

1 reference

7 August 2017

anti-retroviral agent

0 references

author name string

McLeod GX

series ordinal

1

1 reference

7 August 2017

G. X. McLeod

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1324254

13 September 2022

S. M. Hammer

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1324254

13 September 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1324254

13 September 2022

publication date

1 August 1992

1 reference

Hospital practice (Office ed.)

7 August 2017

1 reference

7 August 2017

27 Suppl 2

1 reference

7 August 2017

14-25

1 reference

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

7 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

The effects on survival of early treatment of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Phase I study of 2′-3′-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Two-Drug Combinations of Zidovudine, Didanosine, and Recombinant Interferon- A Inhibit Replication of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Synergistically In Vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Human immunodeficiency virus inhibition is prolonged by 3'-azido-3'-deoxythymidine alternating with 2',3'-dideoxycytidine compared with 3'-azido-3'-deoxythymidine alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Ribavirin antagonizes the effect of azidothymidine on HIV replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

HIV-1 sensitivity to zidovudine and clinical outcome in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Initial clinical experience with dideoxynucleosides as single agents and in combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Alternating and intermittent regimens of zidovudine (3'-azido-3'-deoxythymidine) and dideoxycytidine (2',3'-dideoxycytidine) in the treatment of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Combined treatment of symptomatic human immunodeficiency virus type 1 infection with native interferon-alpha and zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Phase I study of low-dose zidovudine and acyclovir in asymptomatic human immunodeficiency virus seropositive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex with a regimen of 3'-azido-2',3'-dideoxythymidine (azidothymidine or zidovudine) and acyclovir. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

A pilot study of low-dose zidovudine in human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Effects of recombinant human granulocyte colony-stimulating factor on leucopenia in zidovudine-treated patients with AIDS and AIDS related complex, a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F21548331.1992.11705596

10.1080/21548331.1992.11705596

21 January 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference